GEN1047 for Solid Tumors - First in Human (FIH) Trial

Genmab

Status and phase

Active, not recruiting

Phase 2

Phase 1

Conditions

Endometrial Cancer, Endometrial Neoplasm

Squamous Non Small Cell Lung Cancer (NSCLC-SCC)

Breast Cancer, Breast Neoplasms

Ovarian Cancer, Ovarian Neoplasms

Treatments

Biological: GEN1047 is a bispecific antibody that induces T-cell mediated cytotoxicity of B7H4-positive tumor cells.

Study type

Interventional

Funder types

Industry

Identifiers

NCT05180474

GCT1047-01

1007620 (Registry Identifier)

2024-510722-10 (Other Identifier)

NL82658.056.23 (Registry Identifier)

2021-001790-23 (EudraCT Number)

Details and patient eligibility

About

The purpose of this trial is to measure the following in participants with solid tumors who receive GEN1047:

The side effects seen with GEN1047
What the body does with GEN1047 once it is administered
What GEN1047 does to the body once it is administered
How well GEN1047 works against solid tumors

The estimated trial duration for an individual participant is 8 months, consisting of a 28-day screening period, an estimated 3 month treatment period (the duration of treatment may vary for each participant), and an estimated 4 month post-treatment follow-up period (the duration of follow-up may vary for each participant). All participants will receive active drug; no one will be given placebo.

Full description

The trial is an open-label, multi-center safety trial of GEN1047. The trial consists of two parts: a dose escalation part ("escalation" - phase 1) and an expansion part ("expansion" - phase 2a). The goal of the dose escalation part is to find out if GEN1047 is safe in participants with specific solid tumors and to find the best dose(s). In the expansion part of the trial up to two doses of GEN1047 will be tested.

Enrollment

179 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Key Inclusion Criteria:

Criteria - Escalation Part:

Participant must have histologically or cytologically confirmed solid tumor(s) in any of the following selected indications for which there is no further available standard therapy likely to confer clinical benefit (or participant is not a candidate or has previously refused such earlier available therapy), and for whom, in the opinion of the investigator, experimental therapy with GEN1047 may be beneficial (breast cancer, endometrial cancer, ovarian cancer, NSCLC-SCC.
Participants with ovarian cancer must have documented progressive disease (PD) on or after last prior treatment and within 60 days of screening.
Must be at least 18 years of age (or the legal age of consent in the jurisdiction in which the trial is taking place) on the day of signing informed consent.
Must have either recurrence after, or progression on or lack of response to available relevant standard of care (SoC) anticancer therapies; or are deemed intolerant to or ineligible for, standard curative therapy in the recurrent setting.
Must have at least 1 measurable lesion per RECIST v1.1. The measurable lesion(s) must be outside the field of radiation therapy (RT) if there was prior treatment with RT.
Must have an Eastern Cooperative Oncology Group performance status (ECOGPS) score of 0 to 1 at Screening and on C1D1 pretreatment.
Should provide a tumor tissue sample during the Screening period and prior to C1D1.
Provide all tumor-assessing pre-trial CT scans since failure of last prior therapy.

Criteria - Expansion Part Stage 1, 1b and Stage 2:

Participants must have documented PD according to RECIST v1.1 on or after last prior treatment with latest scan performed a maximum of 28 days prior to the first dose.
Participant must have advanced (unresectable) or metastatic, histologically confirmed diagnosis (breast cancer, endometrial cancer, ovarian cancer.
Must be a female and at least 18 years of age (or the legal age of consent in the jurisdiction in which the trial is taking place) at the time of consent.
Must have at least 1 measurable lesion per RECIST v1.1 as assessed by local investigator.
Must have an ECOG- PS score of 0 to 1 at Screening and on Cycle 1 Day 1 (C1D1) pretreatment.
Must submit a tumor tissue sample during the Screening period and prior to C1D1.
Provide all tumor-assessing pre-trial CT scans since failure of last prior therapy.

Key Exclusion Criteria:

Significant cardiovascular impairment within 6 months of the first dose of trial drug.
Participant with new or progressive brain metastases or spinal cord compression.
Participant has been exposed to any prior therapy with a compound targeting CD3 and/or B7H4 or cell based therapies.
Current pneumonitis (any grade) including any radiological change of ongoing pneumonitis at baseline or history of non-infectious drug-, immune-, or radiation-related pneumonitis that required steroid.

Note: Other protocol defined inclusion and exclusion criteria may apply.